secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longevity Health Holdings, Inc. (XAGE)
CIK:        0001842939
Form:       8-K
Filed at:   2025-04-14T23:59:59+00:00
Accession:  0000950170-25-053506
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longevity Health signs merger with 20/20 Biolabs; combined co. valued ~$99M
---------------------------------------------------------------------------

- All-stock merger: 20/20 stockholders to own ~50.1% of combined co. (pre-concurrent financing).
- Combined co. FY2025 revenue forecast to double to ~$7-8M from ~$3-4M; ~$1M synergies expected.
- Post-closing: Jonathan Cohen (20/20 CEO) becomes CEO; Rajiv Shukla remains Chairman.
- Concurrent financing to raise min. $4M gross proceeds; also at-market offering for up to $2M common stock.
- Closing expected Q3 2025; subject to stockholder approvals, Nasdaq listing, and other conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842939/000095017025053506/0000950170-25-053506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842939/000095017025053506/xage-20250411.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-053506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer